CD21 Antibody (B-E5) - Azide and BSA Free
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-14587
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human
Applications
Flow Cytometry, Functional
Label
Unconjugated
Antibody Source
Monoclonal Mouse IgG2a Kappa Clone # B-E5
Format
Azide and BSA Free
Concentration
1 mg/ml
Product Specifications
Immunogen
Daudi cell line
Clonality
Monoclonal
Host
Mouse
Isotype
IgG2a Kappa
Description
Stable at 4C for 12 months.
Hybridoma: Myeloma X63/AG.8653 x Balb/c spleen cells
Hybridoma: Myeloma X63/AG.8653 x Balb/c spleen cells
Scientific Data Images for CD21 Antibody (B-E5) - Azide and BSA Free
Flow Cytometry: CD21 Antibody (B-E5) - Azide and BSA Free [NBP3-14587]
Flow Cytometry: CD21 Antibody (B-E5) [NBP3-14587] - A typical staining pattern with the B-E5 monoclonal antibody of lymphocytes.Applications for CD21 Antibody (B-E5) - Azide and BSA Free
Application
Recommended Usage
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Functional
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Biological Activity: Induces human B-cell proliferation and competes with EBV for CD21 binding.
Formulation, Preparation, and Storage
Purification
Affinity purified
Formulation
PBS. Sterile-filtered through 0.22 um.
Format
Azide and BSA Free
Preservative
No Preservative
Concentration
1 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Background: CD21
Alternate Names
C3DR, CD21, CR2
Gene Symbol
CR2
Additional CD21 Products
Product Documents for CD21 Antibody (B-E5) - Azide and BSA Free
Product Specific Notices for CD21 Antibody (B-E5) - Azide and BSA Free
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...